FORT MYERS — Cancer-testing firm Neogenomics posted a loss in the third quarter from a decrease in Medicare reimbursements and higher research and development expenses.
Continue reading your article with a Business Observer subscription.
What's included:
✓ Unlimited digital access to BusinessObserverFL.com
✓ E-Newspaper app, digital replica of print edition